BACKGROUND: Mutations in are rare oncogene mutations, found in 2% of non-small-cell lung cancers (nsclcs). Little information is available about the management of patients with mutated nsclc, except for those included in clinical trials. We undertook the present study to assess the clinical characteristics, management, and outcomes of those patients in a real-life setting.
METHODS: This retrospective multicentre observational study included all patients with mutated nsclc diagnosed between January 2012 and December 2014.
RESULTS: Patients ( = 59) from 24 centres were included: 57.6% men; mean age: 64.5 ± 14.5 years; 82% with a performance status of 0-1 at diagnosis; smoking status: 40.3% current, 32.6% former; 93% with adenocarcinoma histology; 75% stage iv; 78% with V600E mutations; 2 with and 2 with co-mutations. Of the stage iv patients, 79% received first-line therapy (14.2% anti, and 48% received second-line treatment (23.8% anti Response rate and progression-free survival were, respectively, 51.7% and 8.7 months [95% confidence interval (ci): 6.4 months to 15.2 months] for first-line therapy and 35.3% and 4.1 months (95% ci: 2 months to 10.9 months) for second-line treatments. The 2-year overall survival was 58.5% (95% ci: 45.8% to 74.8%). Outcomes in patients with stage iv nsclc harbouring V600E mutations ( = 32) did not differ significantly from those of patients with other mutations.
CONCLUSIONS: In this real-world analysis, most nsclc patients with a mutation were men and current or former smokers. Survival appears to be better in these mutated patients than in nsclc patients without an oncogenic driver.